Filtered By:
Vaccination: Hepatitis Vaccine
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 256 results found since Jan 2013.
Pain at Hepatitis B Vaccine in Preterm Infants
Condition: Infant, Newborn, Pain Intervention: Behavioral: Palmar grasp reflex Sponsors: Ataturk University; MSc Elif Simay KOÇ Recruiting
Source: ClinicalTrials.gov - January 5, 2023 Category: Research Source Type: clinical trials
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Acute Hepatitis of Unknown Etiology Among Young Children: Research Agenda by the ESPGHAN Hepatology Committee
In April 2022, an increased incidence of acute hepatitis cases of unknown etiology among previously healthy children across the United Kingdom was described. Since, more than 270 cases from the United Kingdom and hundreds more from all across the world have been reported. The majority of affected children were younger than 6 years of age. The clinical presentation was nonspecific with diarrhea and vomiting usually preceding the appearance of jaundice, abdominal pain, nausea, and malaise. Approximately 5% have required liver transplantation. An infectious etiology has been considered likely given the epidemiological and cli...
Source: Journal of Pediatric Gastroenterology and Nutrition - September 23, 2022 Category: Gastroenterology Tags: Societal Paper Source Type: research
Acute hepatitis (Non Hepa A-E) of unknown origin among pediatrics
Infez Med. 2022 Sep 1;30(3):353-361. doi: 10.53854/liim-3003-4. eCollection 2022.ABSTRACTSeveral clusters and individual cases of acute hepatitis have been reported in the US, Europe and recently in Asia and Central America since October 2021. A laboratory investigation of the common viral hepatitis agents (HAV, HBV, HCV, HDV and HEV) yielded negative results prompting the use of the term "acute non HepA-E hepatitis" to describe this condition. As of 24 June of 2022, WHO have reported 920 probable cases of severe acute hepatitis of unknown origin among pediatrics in 33 countries in five WHO regions. Since the previous repo...
Source: Infezioni in Medicina - September 23, 2022 Category: Infectious Diseases Authors: Nasim Asadi Faezi Bahareh Mehramouz Sepehr Taghizadeh Pasquale Pagliano Hossein Samadi Kafil Source Type: research
Stem cells as an ideal carrier for gene therapy: A new approach to the treatment of hepatitis C virus
CONCLUSION: Gene therapy, either directly and in vivo or indirectly and in vitro, requires carriers (vectors) to transfer the gene. These carriers are divided into two groups, viral and non-viral. In indirect gene therapy, living cells are isolated from a person's body and genetically modified. Stem cells have the properties to transfer the desired genes to the patient's body, including the ability to proliferate for a long time and differentiate into the tissue cells in which they are located.PMID:36150664 | DOI:10.1016/j.trim.2022.101721
Source: Transplant Immunology - September 23, 2022 Category: Transplant Surgery Authors: Alireza Rafati Hadi Esmaeili Gouvarchin Ghaleh Afsaneh Azarabadi Mahmood Reza Masoudi Elmira Afrasiab Akbar Ghorbani Alvanegh Source Type: research
Acute hepatitis (Non Hepa A-E) of unknown origin among pediatrics
Infez Med. 2022 Sep 1;30(3):353-361. doi: 10.53854/liim-3003-4. eCollection 2022.ABSTRACTSeveral clusters and individual cases of acute hepatitis have been reported in the US, Europe and recently in Asia and Central America since October 2021. A laboratory investigation of the common viral hepatitis agents (HAV, HBV, HCV, HDV and HEV) yielded negative results prompting the use of the term "acute non HepA-E hepatitis" to describe this condition. As of 24 June of 2022, WHO have reported 920 probable cases of severe acute hepatitis of unknown origin among pediatrics in 33 countries in five WHO regions. Since the previous repo...
Source: Infezioni in Medicina - September 23, 2022 Category: Infectious Diseases Authors: Nasim Asadi Faezi Bahareh Mehramouz Sepehr Taghizadeh Pasquale Pagliano Hossein Samadi Kafil Source Type: research
